Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lurasidone hydrochloride
Drug ID BADD_D01331
Description Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Indications and Usage Treatment of schizophrenia.
Marketing Status approved; investigational
ATC Code N05AE05
DrugBank ID DB08815
KEGG ID D04820
MeSH ID D000069056
PubChem ID 11237860
TTD Drug ID D01QGX
NDC Product Code 76282-524; 51148-001; 66039-897; 76072-1007; 13668-509; 46708-496; 47335-578; 47335-684; 60687-769; 65862-957; 68180-670; 68382-965; 68382-968; 69097-941; 70436-095; 72205-209; 76282-522; 38217-0011; 0904-7355; 51148-002; 53747-058; 58032-2024; 65862-956; 33342-422; 43598-352; 46708-498; 62332-495; 63402-308; 65162-082; 68382-967; 70436-094; 70771-1734; 76282-525; 17373-1185; 38217-0010; 0904-7357; 65977-0103; 16729-349; 47335-685; 65162-881; 68180-672; 70436-093; 70436-097; 68180-674; 70771-1737; 72205-210; 72205-211; 76282-523; 42765-009; 46016-3671; 46016-3672; 72643-031; 16729-346; 33342-423; 43598-355; 47335-639; 65162-879; 65862-955; 67877-639; 67877-640; 67877-641; 68382-859; 72205-207; 50370-0033; 16729-348; 16729-350; 43598-353; 46708-494; 50090-6438; 63402-302; 63402-304; 65862-953; 68180-671; 70518-3762; 70771-1738; 38217-0014; 65015-843; 33342-419; 60687-758; 62332-496; 63402-306; 68180-673; 68382-966; 69097-937; 38217-0012; 0904-7358; 51148-004; 65372-1192; 33342-421; 60687-780; 62332-498; 63402-312; 65162-880; 70771-1736; 38217-0013; 38217-0015; 0904-7359; 65085-0053; 69011-0004; 13668-466; 13668-467; 16729-347; 33342-420; 46708-495; 62332-494; 65162-882; 65862-954; 69097-938; 69097-942; 70771-1735; 72205-208; 76282-534; 51148-003; 46708-497; 47335-579; 60687-747; 62332-497; 67877-638; 67877-642; 69097-939; 70436-096; 0904-7356; 66583-0516; 13668-464; 13668-465; 43598-351; 43598-354
UNII O0P4I5851I
Synonyms Lurasidone Hydrochloride | Hydrochloride, Lurasidone | Lurasidone HCl | HCl, Lurasidone | SM 13496 | 13496, SM | SM13496 | SM-13,496 | SM 13,496 | SM13,496 | SM-13496 | Lurasidone | N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide | Latuda
Chemical Information
Molecular Formula C28H37ClN4O2S
CAS Registry Number 367514-88-3
SMILES C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Rhabdomyolysis15.05.05.002--
Salivary hypersecretion07.06.01.009--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Sudden death02.03.04.013; 08.04.01.003--
Tachycardia02.03.02.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 2th Page    First    Pre   2    Total 2 Pages